Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.12 Million EUR | -19.28% |
| 2022 | 31.12 Million EUR | 29.04% |
| 2021 | 24.12 Million EUR | 32.72% |
| 2020 | 18.17 Million EUR | 22797.11% |
| 2019 | 79.38 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 24.9 Million USD | -7.78% |
| 2024 Q3 | 25.8 Million EUR | 6.82% |
| 2024 Q2 | 24.15 Million EUR | 4.26% |
| 2023 FY | 25.12 Million EUR | -19.28% |
| 2023 Q1 | 27.57 Million EUR | 11.95% |
| 2023 Q2 | 26.1 Million EUR | -5.35% |
| 2023 Q4 | 25.12 Million EUR | 9.17% |
| 2023 Q3 | 23.01 Million EUR | -11.82% |
| 2022 Q4 | 24.63 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -263.505% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 80.828% |
| Adocia SA | 31.87 Million EUR | 21.163% |
| Aelis Farma SA | 13.08 Million EUR | -92.091% |
| Biophytis S.A. | 15.84 Million EUR | -58.53% |
| Advicenne S.A. | 24.37 Million EUR | -3.071% |
| genOway Société anonyme | 14.45 Million EUR | -73.764% |
| IntegraGen SA | 5.97 Million EUR | -320.173% |
| Medesis Pharma S.A. | 6.42 Million EUR | -290.986% |
| Neovacs S.A. | 3.71 Million EUR | -576.85% |
| NFL Biosciences SA | 3.62 Million EUR | -593.944% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -270.454% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -659.054% |
| Sensorion SA | 13.22 Million EUR | -89.952% |
| Theranexus Société Anonyme | 5.01 Million EUR | -400.888% |
| TME Pharma N.V. | 2.78 Million EUR | -802.172% |
| Valbiotis SA | 13.7 Million EUR | -83.291% |
| TheraVet SA | 1.48 Million EUR | -1591.961% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -22.755% |
| argenx SE | 402.79 Million EUR | 93.762% |
| BioSenic S.A. | 32.26 Million EUR | 22.125% |
| Celyad Oncology SA | 9.97 Million EUR | -151.809% |
| DBV Technologies S.A. | 38.74 Million USD | 35.152% |
| Galapagos NV | 1.56 Billion EUR | 98.391% |
| Genfit S.A. | 105.92 Million EUR | 76.279% |
| GeNeuro SA | 20.13 Million EUR | -24.755% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -191.75% |
| Innate Pharma S.A. | 132.29 Million EUR | 81.008% |
| Inventiva S.A. | 101.59 Million EUR | 75.268% |
| MaaT Pharma SA | 22.46 Million EUR | -11.843% |
| MedinCell S.A. | 77.77 Million EUR | 67.693% |
| Nanobiotix S.A. | 95.74 Million EUR | 73.757% |
| Onward Medical N.V. | 25.69 Million EUR | 2.228% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 57.471% |
| Oxurion NV | 19.73 Million EUR | -27.308% |
| Pharming Group N.V. | 228.28 Million EUR | 88.994% |
| Poxel S.A. | 53.9 Million EUR | 53.386% |
| GenSight Biologics S.A. | 34.72 Million EUR | 27.649% |
| Transgene SA | 26.51 Million EUR | 5.248% |
| Financière de Tubize SA | 123.65 Million EUR | 79.68% |
| UCB SA | 6.56 Billion EUR | 99.617% |
| Valneva SE | 341.14 Million EUR | 92.635% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -452.573% |